SARS-2 AmpliVIR

SARS-2 AmpliVIR (also known as AmpliVIR RNA) is an experimental, preclinical-stage RNA interference (RNAi) therapeutic being developed by Halo-Bio RNAi Therapeutics for the treatment of COVID-19 (SARS-CoV-2 viral infection) and early-stage lower respiratory tract infections. Designed as a non-infectious, single-stranded RNA molecule, AmpliVIR RNA is formulated within a nanoparticle (such as a virus-like particle-loaded or cationic lipoplex formulation) for delivery via intrapulmonary inhalation or nasal spray. The therapeutic is designed to be selectively replicated by SARS-CoV-2 viral proteins within infected cells, where it silently competes with the viral lifecycle and utilizes RNAi to suppress subviral gene expression of key viral mRNAs, including Spike (S), Membrane (M), Nucleocapsid (N), and Envelope (E) proteins. This multi-specific gene silencing aims to rapidly halt viral replication, reduce infectivity, and restore balance to the host immune response.

Other names

AmpliVIR RNA